FSTL3 (Follistatin Like 3)
A secreted glycoprotein modulating TGF-β superfamily signaling
Gene Information Card
| Symbol | FSTL3 |
|---|---|
| Full Name | Follistatin Like 3 |
| Gene Type | protein-coding |
| Chromosomal Location | 19p13.3 |
| NCBI Gene ID | 10272 ncbi.nlm.nih.gov/gene/10272 |
| Ensembl ID | ENSG00000105699 |
| UniProt ID | O95633 |
| OMIM ID | 605343 |
| HGNC ID | 3973 |
| Aliases | FLRG, FSRP |
Description
FSTL3 (Follistatin Like 3) encodes a secreted glycoprotein that binds to and inhibits members of the TGF-β superfamily, including activin, myostatin, and BMPs. It plays roles in cell growth, differentiation, and apoptosis, and is implicated in cancer, cardiac hypertrophy, and metabolic disorders.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (various types) | Overexpression of FSTL3 inhibits activin-mediated growth suppression, promoting tumor progression. | NCBI Gene, COSMIC |
| Cardiac hypertrophy | FSTL3 modulates TGF-β signaling in cardiomyocytes, contributing to hypertrophic response. | NCBI Gene, OMIM |
| Metabolic syndrome | Altered FSTL3 levels affect myostatin signaling, influencing muscle mass and insulin sensitivity. | NCBI Gene, ClinVar |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Heart | 12.5 | Medium |
| Placenta | 18.3 | High |
| Skeletal Muscle | 8.2 | Medium |
| Liver | 3.1 | Low |
| Pancreas | 4.7 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HepG2 | 15.2 | Hepatocellular carcinoma cell line |
| K562 | 9.8 | Chronic myeloid leukemia cell line |
| A549 | 6.5 | Lung carcinoma cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G | missense | <0.1% | Unknown functional effect |
| c.200C>T | missense | <0.1% | Reported in ClinVar as uncertain significance |
Mutation functional classification
Loss of Function (LOF)
No well-characterized loss-of-function mutations reported.
Gain of Function (GOF)
Overexpression in tumors suggests potential gain-of-function in cancer.
Dominant Negative (DN)
Not described.
View complete mutation data：
Gene Ontology (GO)
| • extracellular space (GO:0005615) | • growth factor activity (GO:0008083) |
| • activin receptor signaling pathway (GO:0032924) | • identical protein binding (GO:0042802) |
Pathways
• TGF-beta signaling pathway (KEGG: hsa04350)
• Activin receptor signaling (Reactome: R-HSA-1502540)
Protein Summary
FSTL3 is a 263-amino acid secreted glycoprotein containing a follistatin-like domain and a Kazal-type serine protease inhibitor domain. It binds activin, myostatin, and BMPs, blocking their interaction with receptors, thereby modulating TGF-β superfamily signaling. The protein is involved in cell proliferation, differentiation, and apoptosis.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| FSTL3 Knockout HEK293 Cell Line | EDJ-KQ6985 | Human | 10272 | Details Get a Quote |
| FSTL3 Knockout A-549 Cell Line | EDJ-KQ30312 | Human | 10272 | Details Get a Quote |
| FSTL3 Knockout HCT 116 Cell Line | EDJ-KQ31695 | Human | 10272 | Details Get a Quote |
| FSTL3 Knockout HeLa Cell Line | EDJ-KQ31696 | Human | 10272 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
